Curator Dashboard

A private commercial company generating revenues by contract development and manufacturing biopharmaceuticals as well as creating liposomal formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. The R&D projects and technologies are open for co-development and licensing. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals (??63 Austrian Pharmaceutical Law) thus meeting the EU requirements for drug manufacturing. Its core competence is the development and manufacture of biopharmaceuticals, using both mammalian and microbial cell technology. A fine example are Polymun''s broadly neutralizing HIV-1 antibodies produced in CHO cells. Other examples are recombinant human and porcine trypsin produced in yeast. Cell culture was also the basis for the development of a live attenuated influenza vaccine produced in Vero cells which led to the further investigation in genetically modified influenza viruses used as carrier for foreign epitopes (HIV, TB). Also the innovative liposome technology was initiated in order to optimize the formulation of the pharmacologically potent enzyme SOD, produced by Polymun in E. coli. Today, Polymun can apply this drug delivery platform to all kinds of pharmaceutically active ingredients. The industrial applicability in scale and price is a common focus throughout all projects and technologies.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Funding resource that raises funds to support BC Children's Hospital, Sunny Hill Health Centre for Children and the Child and Family Research Institute. The Foundation also works with Sunny Hill's Board of Directors to manage the Sunny Hill Foundation for Children. In 2013, BC Children's Hospital Foundation received donations from more than 150,000 people and had revenues of over $83 million.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A collaborative care and research initiative with a focus on prevention and treatment of Intellectual disability (ID) that is due to inborn errors of metabolism (IEM), which can be treated with diet or drugs. Health care policy and institutional culture is still operating under the old premise that all ID is incurable and thus, many children born with treatable ID are at risk of not being treated. To acknowledge the multidisciplinary scope and the ways in which health care professionals and researchers will collaborate, the goals of the TIDE BC project are demonstrated within a framework of 7 Work Packages: * Implementation of a new Protocol for diagnostic evaluation of ID, focusing of treatable conditions; * Development of infrastructure to facilitate implementation, evaluation and sustainability of the Protocol; * Investments into next generation genomic technologies; * Improving evidence of and access to treatments; * Evaluation and health economy; * Knowledge dissemination; * Education and Mentoring. The objectives addressed in all Work Packages reflect a highly integrated cluster combining clinical care, research, evaluation, and knowledge dissemination.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

THIS RESOURCE IS NO LONGER IN SERVICE, documented on March 19, 2012. Due to budgetary constraints, the National Center for Biotechnology Information (NCBI) has discontinued support for the NCBI GENSAT database, and it has been removed from the Entrez System. The Gene Expression Nervous System Atlas (GENSAT) project involves the large-scale creation of transgenic mouse lines expressing green fluorescent protein (GFP) reporter or Cre recombinase under control of the BAC promoter in specific neural and glial cell populations. BAC expression data for all the lines generated (over 1300 lines) are available in online, searchable databases (www.gensat.org and the Database of GENSAT BAC-Cre driver lines). If you have any specific questions, please feel free to contact us at info_at_ncbi.nlm.nih.gov The GENSAT project aims to map the expression of genes in the central nervous system of the mouse, using both in situ hybridization and transgenic mouse techniques. Search criteria include gene names, gene symbols, gene aliases and synonyms, mouse ages, and imaging protocols. Mouse ages are restricted to E10.5 (embryonic day 10.5), E15.5 (embryonic day 15.5), P7 (postnatal day 7), and Adult (adult). The project focuses on two techniques * Evaluation of unmodified mice lines for expression of a given gene using radiolabelled riboprobes and in-situ hybridization. * Creation of transgenic mice lines containing a BAC construct that expresses a marker gene in the same environment as the native gene

• Resource
• SciCrunch
• 17 years ago - by Anonymous

Behavioral and 3T MR imaging data from over 500 healthy adult participants with 14 subjects also scanned in resting-state MEG (rMEG) and task MEG (tMEG). Highlights: * Behavioral and demographic data on 550 subjects. * MR imaging data preprocessed using updated pipelines (structural pipeline v3.1, functional pipeline v3.1, diffusion pipeline v3.1, task analysis pipeline v3.3). * Updates to pipelines include a new intersubject registration method called MSMSulc. All MR data from Q1-Q3 releases have been reprocessed. HCP strongly advises against mixing data from this release with previously-released data. * Individual task fMRI grayordinate-based analysis results (available at 2mm, 4mm, 8mm, and 12mm smoothing levels) and volume-based analysis results (4mm smoothing) are available for all complete 500 Subjects tfMRI data, using an updated task analysis pipeline v3.3. * New extensively processed 100- and 400+-subject group-average functional MR data. * Updates to MEG data and access in ConnectomeDB. Structural MRI-based MEG anatomical models and MR data for the 14 MEG1 Release subjects. * Improvements to behavioral data organization and data dictionary, including the addition of previously unreleased restricted behavioral and demographic data. * All imaging data soon to be available on the cloud through Amazon S3. (More information to come!)

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Service that extracts and analyzes methodological information from thousands of published studies across the functional neuroimaging literature. It currently offers searching articles by methodological choices, visualization of methods trends over time, and extraction of methods information from text. It currently includes 282,476 methodological details about 21,562 articles, published between 1992 and 2014. (2014) * Search for articles by title, authors, and methods. * Interactive visualizations of methodological parameters over time, by author, and more. * All data are programmatically accessible through a simple application programming interface. It''s simple to re-analyze the data or integrate with your own application.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Center for excellence research in genomic medicine, focusing on the comprehensive study and understanding of the genetic basis of human diseases in general, placing special emphasis on cancer and its genetic disorders related to inheritance. GENYO was created as a multidisciplinary research space, where different professionals from the healthcare, university and business areas interact, making it possible to generate new systems to diagnose, prevent and treat diseases based on the joint and coordinated application of first-rate knowledge in the different areas of genetics. The center is the benchmark center of the Andalusian Program for Research in Clinical Genetics and Genomic Medicine, a program which, together with those of Cell Therapy and Regenerative Medicine, and Nanomedicine have the main objective of supporting and fostering translational research in Advanced Therapies. The activities performed within these three research programs are developed in coordination with the Andalusian Initiative for Advanced Therapies (IATA), an initiative of the Andalusian Government promoted by the Regional Ministries of Health and Innovation, Science and Enterprise.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A Swiss service and consulting company specialized in the computational analysis of biomarker data from clinical trials. Their technical expertise spans across multiple biomaker technological platforms such as genetics, transcriptomics, protein assays and cellular assays. Quartz Bio is a spin-off of Merck Serono with the capital of the company entirely owned by its employees.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A biomedical company in Spain focused on the development of new tools for diagnosis and personalized treatment of oncological diseases and precancerous. It has three areas of activity in permanent innovation: Assistance in Diagnosis / Prognosis in solid and hematological tumors, Translational Research covering the gap between basic and clinical research and advanced radiotherapy treatments based image-guided single dose (SD-IGRT). Their objectives are: * Provide an integrated tissue and tumor molecular phenotype analysis using the most advanced technologies in diagnosis, to guide the most appropriate treatment for each patient. * Discover and validate molecular patterns by molecular systems and platforms including pathology, to generate predictive algorithms through computational biology, evolution and determining the response of patients with a particular tumor profile. Althia has laboratories equipped with the most advanced equipment and technologies in Barcelona and Granada Genyo Center, with offices in Madrid.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A research center focused on cellular medicine, where the basic research focuses and works on relevant clinical matters and fosters economic development. The center manages the research of the Bellvitge University Hospital, the Institut Catal�� d''Oncologia (Catalan Institute of Oncology) and the University of Barcelona. It is one of the first five Spanish research centers accredited as health research institute by the Instituto de Salud Carlos III (Health Institute Carlos III).

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Commercial organization that develops pre-competitive solutions to the knowledge challenges facing drug discovery by connecting companies, leading academics and biotech specialists. It provides the bandwidth, knowledge and experience to successfully deliver pre-competitive projects through leadership, technical consulting, workflow expertise and software production. They possess over 30 years collective experience of large pharma drug discovery, computational science and knowledge management experience.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Ontology of SNOMED (Systematized Nomenclature of Medicine) clinical terms.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A multitechnological applied non-profit research organisation in Northern Europe that provides high-end technology solutions and innovation services. They enhance their customers'' competitiveness, thereby creating prerequisites for society''s sustainable development, employment, and well-being. VTT has ISO9001:2008 certificate and ISO14001:2004 certificate.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Each month our podcast team will be broadcasting the very latest breakthroughs and discoveries in neurosciences, psychiatry and psychology.

• Resource
• SciCrunch
• 16 years ago - by Anonymous

Academic cancer research center, a postgrad college, and a charity in the United Kingdom that is making discoveries that defeat cancer. With their partners The Royal Marsden NHS Foundation Trust they form the largest comprehensive cancer center in Europe and perform high quality and original basic research and translational studies, with the aim of developing better treatments for the benefit of cancer patients worldwide. The ICR offers comprehensive, modern facilities for research and studentships supported by the Wellcome Trust, MRC, CRUK and EPSRC and the ICR''s own resources which are awarded on a competitive basis. The ICR offers postgraduate research degrees (MPhil, PhD and MD (Res)) and a modular postgraduate taught degree in oncology aimed at clinicians undertaking specialist training in the field of Clinical or Medical Oncology leading to a Postgraduate Certificate, Postgraduate Diploma or MSc in Oncology.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A globally operating Finnish developer, manufacturer and marketer of human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. They are continuously developing new drugs and treatment methods. Pharmaceutical RD focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A commercial organization with expertise and multiple departments that focus on both fish physiology and molecular cell biology. ZF-pharma has developed patented technology for the automated in vivo high-throughput screening of pharmaceutical drug candidates against diseases. They seek industrial partners that are interested in obtaining a license for this technology or, alternatively, would prefer to outsource screening of TB drugs to ZF-pharma. NewCatch BV has developed a tool for use in sustainable aquaculture. The tool will first be used for reproduction of the highly valued fish species eel, pikeperch and sole. They seek industrial / aquaculture partners interested in obtaining a license for ZF-implants in other fish species. NewCatch BV carries out fish reproductive research, for instance European eel (Anguilla anguilla), exploring maturation and reproduction. ZF-Genomics offers multiple sequencing services, including mRNAseq and microRNA analysis and de novo and reference genome assemblies. In addition they also offer the bioinformatics services that are needed to make sense of the sequence data. In addition, they perform Next generation sequencing tasks for (inter)national research project partners and for external customers.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

A UK national induced pluripotent stem (iPS) cell resource that will create and characterize more than 1000 human iPSCs from healthy and diseased tissue for use in cellular genetic studies. Between 2013 and 2016 they aim to generate iPS cells from over 500 healthy individuals and 500 individuals with genetic disease. They will then use these cells to discover how genomic variation impacts on cellular phenotype and identify new disease mechanisms. Strong links with NHS investigators will ensure that studies on the disease-associated cell lines will be linked to extensive clinical information. Further key features of the project are an open access model of data sharing; engagement of the wider clinical genetics community in selecting patient samples; and provision of dedicated laboratory space for collaborative cell phenotyping and differentiation.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Non-profit organization that facilitates co-operation between professionals in biotechnology and the life sciences all over Europe bringing research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.

• Resource
• SciCrunch
• 12 years ago - by Anonymous

Organization that provides academic and industrial clients access to functional genomics technologies, services and partnering solutions including genome-wide expression, copy number profiling, miRNA expression, DNA-protein interaction (ChIP-on-chip), Illumina high-throughput sequencing including nucleic acid quality and quantity assessment. For gene silencing and ectopic expression purposes, they offer high-titer shRNA and ORF lentiviruses targeting genes of interest. They also offer customized services e.g. preparation of gain or loss-of-function cell lines and protein interactomics-based services (yeast two-hybrid). In addition, they provide access to wide array of computational data analyses. BMGen also offers partnering deals for clients interested in customized integration of several technologies.

• Resource
• SciCrunch
• 12 years ago - by Anonymous